1 The global obesity drug market is projected to reach $150 billion by 2035 as GLP-1s continue to evolve in terms of maturation and diversification, according to Clarivate
"That tension really and that price negotiation is a very big reason why we have such a successful and sustainable Pharmaceutical Benefits Scheme." Semaglutide, which is sold under the brand name Ozempic, is already listed on the PBS for people with type 2 diabetes and Wegovy, with the same active ingredient, has been recommended for PBS listing
Subscribe for evidence-based best practices and to discover the outcomes
That extra pathway is scientifically interesting, but it does not automatically answer practical questions about eligibility, long-term safety, tolerability, access, or cost
it may only be used lawfully within an authorised clinical trial or MHRA-regulated framework
Animal Early human IBD/ulcerative-colitis trials of BPC-157 (PL-14736) reported it as safe with no reported toxicity but these clinical trials were not completed or fully published